N/A
N=18
Immune Dysfunction in Allergic Asthma
Asthma
Bottom Line
View on ClinicalTrials.gov: NCT00189228 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcome: Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of the Response Curve. Final Values Are Derived From ELISA Units and the Serum Dilution — 18 Units of anti-KLH antibody — p=<0.01
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Xolair (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of New Mexico
- Primary completion
- Jun 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of the Response Curve. Final Values Are Derived From ELISA Units and the Serum Dilution |
18 | <0.01 sig |
Summary
We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.
Eligibility Criteria
Inclusion Criteria
Mild asthma, adults -
Exclusion Criteria
children. on inhaled or systemic steroids
-
Data sourced from ClinicalTrials.gov (NCT00189228). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.